Anaplastic Thyroid Cancer

Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 153)

Abstract

Although the majority of thyroid cancer patients presenting to our surgical endocrinology clinics present with resectable and often curable disease, patients may rarely present with a history and physical findings suggestive of an anaplastic thyroid cancer. The endocrine surgeon should recognize, diagnose, and treat this patient urgently and promptly. The clinical course and findings from two patients who presented to our endocrine surgery clinic recently are summarized below from the patients’ clinical notes.

Keywords

Toxicity Lymphoma Tyrosine Fractionation Paclitaxel 

References

  1. 1.
    Are C, Shaha AR (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453–464CrossRefPubMedGoogle Scholar
  2. 2.
    Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 83:2638–2648CrossRefPubMedGoogle Scholar
  3. 3.
    Demeter JG, De Jong SA, Lawrence AM, Paloyan E (1991) Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 110:956–961; discussion 961–963Google Scholar
  4. 4.
    Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404CrossRefPubMedGoogle Scholar
  5. 5.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X (2005) Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103:2261–2268CrossRefPubMedGoogle Scholar
  6. 6.
    Tallini G, Santoro M, Helie M et al (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287–294PubMedGoogle Scholar
  7. 7.
    McIver B, Hay ID, Giuffrida DF et al (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028–1034CrossRefPubMedGoogle Scholar
  8. 8.
    Tennvall J, Lundell G, Wahlberg P et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848–1853CrossRefPubMedGoogle Scholar
  9. 9.
    Haigh PI, Ituarte PH, Wu HS et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335–2342CrossRefPubMedGoogle Scholar
  10. 10.
    Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA (1990) Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66:321–330Google Scholar
  11. 11.
    Nilsson O, Lindeberg J, Zedenius J et al (1998) Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 22:725–730CrossRefPubMedGoogle Scholar
  12. 12.
    Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J (2006) Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107:1786–1792CrossRefPubMedGoogle Scholar
  13. 13.
    Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594Google Scholar
  14. 14.
    Ain KB, Tofiq S, Taylor KD (1996) Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650–3653CrossRefPubMedGoogle Scholar
  15. 15.
    Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ (2005) Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 131:585–590CrossRefPubMedGoogle Scholar
  16. 16.
    Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A (2000) Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60:650–656PubMedGoogle Scholar
  17. 17.
    Xu G, Pan J, Martin C, Yeung SC (2001) Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86:1769–1777CrossRefPubMedGoogle Scholar
  18. 18.
    Dackiw A, Pan J, Xu G, Yeung SC (2005) Modulation of parathyroid hormone-related protein levels (PTHrP) in anaplastic thyroid cancer. Surgery 138:456–463CrossRefPubMedGoogle Scholar
  19. 19.
    Nagayama Y, Yokoi H, Takeda K et al (2000) Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85:4081–4086CrossRefPubMedGoogle Scholar
  20. 20.
    Narimatsu M, Nagayama Y, Akino K et al (1998) Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 83:3668–3672CrossRefPubMedGoogle Scholar
  21. 21.
    Copland JA, Marlow LA, Kurakata S et al (2006) Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25:2304–2317CrossRefPubMedGoogle Scholar
  22. 22.
    Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17–44CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Surgery, Division of Endocrine and Oncologic Surgery, Section of Endocrine Surgery, Johns Hopkins HospitalJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations